About this trial
The aim of the study is to evaluate the efficacy and safety of a combined approach of cryotherapy and tirbanibulin for the treatment of actinic keratosis of the scalp and forehead, repeated every 4 months. A higher rate of complete response is expected with this combination compared to cryotherapy alone, as well as a better response with repeated treatment cycles.
Eligibility criteria
Qualifiers
Subject over 18 years old presenting with ≥ 8 typical actinic keratoses (AK), clinically visible or palpable, grade I or II, with at least 4 AK per hemiscalp,
Participants who, in the investigator's judgment, are in good general condition (ECOG ≤ 2),
The AK must be distributed in 2 non-overlapping areas, and of similar grades,
Patient capable of understanding and adhering to the study visit schedule and other protocol requirements,
Disqualifiers
Clinically atypical and/or rapidly evolving actinic keratoses (AK) in the treatment area, and grade 3 AK according to Olsen classification,
Located somewhere other than the scalp and/or forehead,
Within 5 cm of a wound that is not fully healed or a lesion suspicious for carcinoma,
Prior treatment with tirbanibulin,
Trial design
Treatments tested in this trial
- Cryotherapy + Tirbanibulin
Treatment groups
Locations
Sponsors and collaborators
University Hospital, Lille
Lead sponsor
Almirall, SAS
Collaborator